Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian Cancer Is Feasible With High Completion Rates, Low Complications, and Acceptable Patient Outcomes
- 1 February 2012
- journal article
- research article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 22 (2), 232-237
- https://doi.org/10.1097/igc.0b013e318234f833
Abstract
Objectives Three large randomized clinical trials have shown a survival benefit for patients treated with intraperitoneal (IP) compared with intravenous chemotherapy for advanced stage epithelial ovarian cancer (EOC). However, the use of IP chemotherapy in recurrent EOC is controversial. The purpose of this study was to determine outcomes, completion rates, and frequency of complications in patients with platinum-sensitive recurrent EOC treated with IP chemotherapy. Methods A retrospective, single-institution analysis of women who received IP chemotherapy for recurrent EOC from January 2003 to April 2010 was conducted. Study patients were identified from the Tumor Registry and office records. Demographic factors, stage, histology, surgical findings, cytoreduction status, and subsequent therapies were abstracted. Progression-free (PFS) and overall survival (OS) were estimated by Kaplan-Meier methods. Results Fifty-six women who received IP chemotherapy for their first EOC recurrence were identified. The mean age of patients was 56.7 years (range, 40–79 y). Fifty-five patients (98.3%) had previously completed at least 6 cycles of intravenous chemotherapy. Of all patients, 87.5% were initially diagnosed with advanced stage disease (stage IIA–IV). All patients underwent secondary cytoreduction at the time of IP port placement. Moreover, 67.9% of patients were considered optimally cytoreduced (Conclusions Intraperitoneal chemotherapy is a feasible option for patients with recurrent EOC, with high completion rates, low frequency of complications, and acceptable PFS and OS.Keywords
This publication has 23 references indexed in Scilit:
- Phase II Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel in Patients With Suboptimal Residual Epithelial Ovarian or Primary Peritoneal CancerInternational Journal of Gynecologic Cancer, 2009
- Survival After Second-Line Intraperitoneal Therapy for the Treatment of Epithelial Ovarian Cancer: The Gynecologic Oncology Group ExperienceInternational Journal of Gynecologic Cancer, 2009
- Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxelGynecologic Oncology, 2006
- Intraperitoneal Chemotherapy in Ovarian Cancer Remains ExperimentalJournal of Clinical Oncology, 2006
- Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup studyGynecologic Oncology, 2006
- Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5International Journal of Gynecologic Cancer, 2003
- Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-AnalysisJournal of Clinical Oncology, 2002
- Intraperitoneal Chemotherapy for Ovarian Carcinoma: Results of Long-Term Follow-UpJournal of Clinical Oncology, 2002
- A Phase II Trial of Intraperitoneal Cisplatin and Etoposide as Consolidation Therapy in Patients with Stage II–IV Epithelial Ovarian Cancer Following Negative Surgical AssessmentGynecologic Oncology, 1998